NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat lung cancer: drug duo targets KRAS mutation
Disease control Not yet recruitingThis study tests two drugs, Glecirasib and Ivonescimab, for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C and a protein called PD-L1. The goal is to see if the combination is safe and can shrink tumors. About 42 adults who have n…
Matched conditions: NSCLC STAGE IV
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
Can a dose increase control lung cancer that Isn't shrinking?
Disease control Not yet recruitingThis study tests whether a higher dose (160 mg) of the drug firmonertinib can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer whose tumors have stayed stable but not shrunk after 8 weeks on the standard 80 mg dose. About 28 adults aged 18-75 with …
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 22, 2026 13:54 UTC